IBL Healthcare aims to triple revenue by 2030

When IBL Healthcare Ltd (IBLHL) sat down with analysts in November, the message was a mix of celebration and caution. The health and wellness distributor has just posted its strongest year on record, riding the same wave of deregulated prices and volume recovery that lifted much of Pakistan’s regulated healthcare sector in 2025. But the first quarter of financial year 2026 already hints at a slower tempo — and a future in which growth will depend less on price resets and more on a deliberate push into artificial sweeteners, cold and flu remedies, and new wellness categories.

At the heart of the strategy is a bold target: to triple the size of the company by 2030, anchored in Stevia-based sweeteners and over-the-counter cold, cough and flu brands, with women’s health and holistic adult nutrition as the next frontiers.